Science and Research

ONL1204(GA): A Phase 1b Multicenter, Randomized, Single-dose Study of the Safety and Tolerability of ONL1204 Ophthalmic solution in patients with Geographic Atrophy (GA) associated with Age-related Macular Degeneration (AMD).

This study evaluates the safety and tolerability of ONL1204 Ophthalmic Solution in patients with geographic atrophy associated with age-related macular degeneration (AMD).


The purpose of this study is to evaluate the safety and tolerability of intravitreal injection of ONL1204 Ophthalmic Solution in patients with geographic atrophy associated with AMD.

GA associated with AMD is one of the world’s leading causes of visual disability. It is a progressive disease with no approved therapy to slow or arrest the process of continual photoreceptor and retinal epithelial (RPE) cell loss.

A safe and effective therapy for GA will have vast societal benefits.

ONL1204 is being developed for this purpose. ONL1204 is a first-in-class inhibitor of fragment apoptosis stimulator receptor-mediated cell death in development for to reduce rates of vision in patients with GA associated with AMD.

ONL1204 has demonstrated protection of multiple retinal cell types in several preclinical models of acute ocular injury and the protection of RPE in AMD models. ONL1204 Ophthalmic Solution is currently in a Phase 1 clinical study in patients with macula-off retinal detachment to evaluate safety and tolerability of a single-dose of ONL1204 Ophthalmic Solution.

The study is ongoing and uses the same doses and route of administration as this Phase 1b study in patients with GA.

  • Principal Investigator
Professor Robyn Guymer AM

Learn more

View this study on ClinicalTrials.gov

See the ClinicalTrials.gov database listing for more detailed information about this study.